About US
Contact us
Position：Home > Phexcom News >
-
Bloomberg: Valeant had planned to expand Philidor relationship before scandal hitValeant Pharmaceuticals ($VRX) disowned its Philidor specialty pharmacy fairly quickly after major questions arose about their relationship. But till those concerns went public, the Quebec-based drugm2015/11/5
-
In snit over supply, not prices, MSF urges South Africa to override AbbVie drug patentDoctors Without Borders (MSF) often has a bone to pick with Big Pharma, especially when it comes to the industry's patents on expensive life-extending meds. As part of its latest campaign, the group i2015/11/4
-
House Democrats launch pharma-pricing task force, vow 'meaningful action' on drug costsDrugmakers would like the political backlash against price increases to go away. Instead, it just keeps growing. Following up on price-squashing proposals from presidential candidatesHillary Clintonan2015/11/4
-
Good thing Bayer's in Germany, CEO says. U.S. business culture is too impatientBayerCEOMarijnDekkers--at one time a wannabe professional tennis player--knows what it is to push it to the limit. But he also knows that too much pushing can take its toll. "I'm very aware of the st2015/11/4
-
Patent challenger Bass wins IP reviews for Celgene, Shire medsChalk up a win for pharma patent challengerKyle Bass. The U.S. Patent and Trademark Office (PTO) has agreed to institute trials for 6 of the drug patents he's challenged--and IP shields for Celgene's2015/11/2
-
'Pfizergan' deal talks draw tax inversion opposition from Clinton, TrumpPfizer and Allergan--which both confirmed on Thursday that they're in "friendly" deal talks--may be intrigued with the prospect of a tie-up. But politicians gung-ho about stopping tax inversions? Not2015/11/2
-
Valeant cuts ties with shadowy pharmacy PhilidorValeant ($VRX) is severing all ties with the specialty pharmacy--which a short seller recently claimed it used to inflate its top line--after reports that Philidor altered doctors' orders to squeeze m2015/11/2
-
Sanofi's Q3 bombshell: Diabetes sales drop, and will keep dropping through 2018Sanofi ($SNY) racked up big third-quarter gains in emerging markets, itsGenzymeunit sales were up almost one-third, and vaccines and animal health delivered growth, too. Overall sales increased by 3.42015/10/30
-
Sanofi recalls all of its Auvi-Q devices, undercutting its push to steal EpiPen market shareA couple of years ago, Sanofi ($SNY) released an epinephrine injection device that gives audio and visual cues for caregivers, hoping the high-tech pen could grab some of the sales from Mylan whoseEpi2015/10/30
-
Allergan pays $125M to rid itself of marketing charges tied to Warner ChilcottAllergan ($AGN) has been trying for months to resolve bribery allegations that came with its $8.5 billion buyout of Warner Chilcott and now will do that with a plea deal and a $125 million payment. Fo2015/10/30